You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A noninvasive optical imaging of retinal amyloid beta deposits in AD patients

    SBC: NEUROVISION IMAGING, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive and invariably fatal degenerative dementia and the most common form of dementia that currently affects over 5 million Americans. The quality of life and economic costs are significant with estimated U.S. health care payments of over 200 billion in 2012, plus unpaid care by over 15 million Americans that is valued ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Modulation of the Innate Immune System by Fisetin for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. An intravaginal ring for real-time evaluation of adherence to topical vagina

    SBC: AURITEC PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to accurate evaluation of efficacy. A better understanding of the true adherence to a preventative therapy w ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Identification and Validation of Targets of Phenotypic High Throughput Screening

    SBC: COLLABORATIVE DRUG DISCOVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Novel indication for myeloid progenitor use: Induction of tolerance

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppression, while retaining the ability to fight infections, ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru

    SBC: DFH Pharma, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Bacterial fermentation in skin microbiome as probiotics (Bfismp) against S. aureu

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Bacterial interference creates an ecological competition between commensal bacteria and pathogenic species. Like microbial competition via fermentation in a ripening fruit, bacterial interference via fermentation has been found in the deep-seated skin abscesses where is an anaerobic microenvironment, allowing bacteria to ferment carbohydrates to short-chain fa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government